Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus
Open Access
- 27 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Abstract
Multiple studies have explored the potential role of programmed death-ligand 1 (PD-L1) as a mediator of Myeloid-derived suppressor cells (MDSCs) effects in various cancers. However, the role PD-L1 expression in MDSCs on autoimmune disease is still largely unknown.This study was undertaken to whether MDSC expressing PD-L1 have more potent immunoregulatory activity and control autoimmunity more effectively in two murine models of lupus (MRL/lpr mice and Roquinsan/san mice). The populations of MDSC were increased in peripheral blood of lupus patients. The mRNA levels of immunosuppressive molecules were profoundly decreased in MDSCs from lupus patients and mice. Co-culture with splenocytes showed that PD-L1 expressing MDSCs from control mice expand both Treg cells and regulatory B cells more potently. Infusion of PD-L1 expressing MDSCs reduced autoantibody levels and degree of proteinuria and improved renal pathology of two animal models of lupus. Moreover, PD-L1 expressing MDSCs therapy can suppress double negative (CD4-CD8-CD3+) T cells, the major pathogenic immune cells and follicular helper T cells in MRL/lpr mice, and podocyte damage. Our results indicate PD-L1 expressing MDSCs have more potent immunoregualtory activity and ameliorate autoimmunity more profoundly. These findings suggest PD-L1 expressing MDSCs be a promising therapeutic strategy targeting systemic autoimmune diseases.Keywords
Funding Information
- National Research Foundation of Korea
This publication has 31 references indexed in Scilit:
- Granulocytic myeloid-derived suppressor cells contribute to IFN-I signaling activation of B cells and disease progression through the lncRNA NEAT1-BAFF axis in systemic lupus erythematosusBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- Increased CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells Correlate With Disease Severity in Systemic Lupus Erythematosus Patients in an iNOS-Dependent MannerFrontiers in Immunology, 2019
- New insights into the immunopathogenesis of systemic lupus erythematosusNature Reviews Rheumatology, 2016
- Myeloid-derived suppressor cells contribute to systemic lupus erythaematosus by regulating differentiation of Th17 cells and TregsClinical Science, 2016
- Myeloid‐Derived Suppressor Cells Induce the Expansion of Regulatory B Cells and Ameliorate Autoimmunity in the Sanroque Mouse Model of Systemic Lupus ErythematosusArthritis & Rheumatology, 2016
- Arginase-1–dependent promotion of T H 17 differentiation and disease progression by MDSCs in systemic lupus erythematosusScience Translational Medicine, 2016
- Immunosuppressive CD11b+Ly6Chi monocytes in pristane-induced lupus mouse modelJournal of Leukocyte Biology, 2015
- Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T CellsThe Journal of Immunology, 2013
- Systemic Lupus ErythematosusNew England Journal of Medicine, 2011
- IL-12 Deficiency in MRL- Fas lpr Mice Delays Nephritis and Intrarenal IFN-γ Expression, and Diminishes Systemic PathologyThe Journal of Immunology, 2003